Intense multidisciplinary research has provided detailed knowledge of the molecular pathogenesis
of Alzheimer disease (AD). This knowledge has been translated into new therapeutic …

Background Alzheimer's disease biomarkers are important for early diagnosis in routine
clinical practice and research. Three core CSF biomarkers for the diagnosis of Alzheimer's …

Background Disease-modifying treatment strategies for Alzheimer's disease have led to an
urgent need for biomarkers to identify the disease at a very early stage. Here, we assess the …

Alzheimer's disease (AD) is the leading cause of dementia, and because the primary risk
factor for AD is old age, the prevalence of the disease is increasing dramatically with ageing …

Mild traumatic brain injury (TBI), which is defined as a head trauma resulting in a brief loss of
consciousness and/or alteration of mental state, is usually benign, but occasionally causes …

Accumulating data from the clinical research support that the core Alzheimer's disease (AD)
cerebrospinal fluid (CSF) biomarkers amyloid‐β (Aβ42), total tau (T‐tau), and …

Background CSF and PET biomarkers of amyloid β and tau accurately detect Alzheimer's
disease pathology, but the invasiveness, high cost, and poor availability of these detection …

Importance There are limitations in current diagnostic testing approaches for Alzheimer
disease (AD). Objective To examine plasma tau phosphorylated at threonine 217 (P-tau217) as …

Neuroaxonal damage is the pathological substrate of permanent disability in various
neurological disorders. Reliable quantification and longitudinal follow-up of such damage are …

Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer’s disease (AD),
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-…